Dasatinib (BMS‐354825) is an inhibitor of Bcr‐Abl and Src kinases that has been shown to be an effective treatment of chronic myeloid leukaemia (CML) and Philadelphia chromosome–positive acute lymphoblastic leukaemia.19, 20. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.